t**u 发帖数: 1572 | 1 Rodman & Renshaw raised Adventrx's price target to $16, | S***7 发帖数: 657 | 2 It seems you like to recommend picks but never give reasons. Can you give
more info? | t**u 发帖数: 1572 | 3 Rodman & Renshaw raised Adventrx's price target to $16,
【在 S***7 的大作中提到】 : It seems you like to recommend picks but never give reasons. Can you give : more info?
| a****c 发帖数: 339 | 4 In my limited experience, this kind of price target never materialize. This
kind of news always lags behind. | s**********9 发帖数: 846 | | w*********7 发帖数: 2883 | | L*******B 发帖数: 837 | 7 Adventrx: FDA Rejects New Drug Application For Lung Cancer Treatment
Adventrx: FDA Rejects New Drug Application For Lung Cancer Treatment
DOW JONES NEWSWIRES
Adventrx Pharmaceuticals Inc. (ANX) said the U.S. Food and Drug
Administration couldn't approve its new drug application for lung-cancer
treatment Exelbine.
Shares in the development-stage drug maker plunged 61%, to 99 cents after
hours, on the news. Through the close, the stock had been up 25% over the
last year, better than the broader market.
The company said it was disappointed by the decision about the treatment for
nonsmall-cell lung cancer, adding that it wasn't in good position to
comment on the future of the Exelbine program until it has a chance to meet
with the FDA. It plans to request a type-A meeting--which is designed to
resolve an issue with an otherwise stalled product--next week. Type-A
meetings are meant to be scheduled within 30 days of such a request.
"In the meantime, our resources and focus are on ANX-188 and ANX-514, which
we believe are the long-term value drivers for our company," Chief Executive
Brian M. Culley said. He was referring to a drug for sickle-cell crisis and
a reformation of the Taxotere cancer treatment, respectively.
In its complete response letter, the FDA said the authenticity of drug
products used in a trial couldn't be verified, which threw the trial's
results into question. Adventrx must repeat the bioequivalence trial, the
FDA said in the letter.
The company said it believes the authenticity of the drug products used in
the pivotal study is verifiable.
The letter also requested information about product quality. |
|